Kura Oncology (KURA) Competitors $9.74 -0.23 (-2.31%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends KURA vs. MRUS, ACAD, TWST, MOR, VCEL, SWTX, ZLAB, KYMR, GMTX, and VERAShould you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Merus (MRUS), ACADIA Pharmaceuticals (ACAD), Twist Bioscience (TWST), MorphoSys (MOR), Vericel (VCEL), SpringWorks Therapeutics (SWTX), Zai Lab (ZLAB), Kymera Therapeutics (KYMR), Gemini Therapeutics (GMTX), and Vera Therapeutics (VERA). These companies are all part of the "pharmaceutical products" industry. Kura Oncology vs. Merus ACADIA Pharmaceuticals Twist Bioscience MorphoSys Vericel SpringWorks Therapeutics Zai Lab Kymera Therapeutics Gemini Therapeutics Vera Therapeutics Merus (NASDAQ:MRUS) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and community ranking. Does the MarketBeat Community believe in MRUS or KURA? Kura Oncology received 72 more outperform votes than Merus when rated by MarketBeat users. Likewise, 69.56% of users gave Kura Oncology an outperform vote while only 67.11% of users gave Merus an outperform vote. CompanyUnderperformOutperformMerusOutperform Votes35367.11% Underperform Votes17332.89% Kura OncologyOutperform Votes42569.56% Underperform Votes18630.44% Does the media prefer MRUS or KURA? In the previous week, Merus had 10 more articles in the media than Kura Oncology. MarketBeat recorded 13 mentions for Merus and 3 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 0.96 beat Merus' score of 0.54 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merus 4 Very Positive mention(s) 0 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Kura Oncology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend MRUS or KURA? Merus currently has a consensus target price of $85.64, suggesting a potential upside of 90.73%. Kura Oncology has a consensus target price of $29.38, suggesting a potential upside of 201.59%. Given Kura Oncology's higher probable upside, analysts plainly believe Kura Oncology is more favorable than Merus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Merus 0 Sell rating(s) 0 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.14Kura Oncology 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk & volatility, MRUS or KURA? Merus has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Do institutionals & insiders have more ownership in MRUS or KURA? 96.1% of Merus shares are owned by institutional investors. 4.6% of Merus shares are owned by insiders. Comparatively, 5.5% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is MRUS or KURA more profitable? Kura Oncology has a net margin of 0.00% compared to Merus' net margin of -680.61%. Merus' return on equity of -38.89% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Merus-680.61% -38.89% -31.16% Kura Oncology N/A -44.09%-39.57% Which has higher valuation and earnings, MRUS or KURA? Kura Oncology has lower revenue, but higher earnings than Merus. Merus is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMerus$35.93M85.55-$154.94M-$3.95-11.37Kura OncologyN/AN/A-$152.63M-$2.36-4.13 SummaryMerus and Kura Oncology tied by winning 9 of the 18 factors compared between the two stocks. Ad Porter & CompanyMusk threatens Liberal’s fake “energy crisis”Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Kura Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KURA vs. The Competition Export to ExcelMetricKura OncologyPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$757.42M$6.87B$5.18B$9.31BDividend YieldN/A3.06%4.78%4.06%P/E Ratio-4.1310.80127.8817.55Price / SalesN/A286.451,262.65139.48Price / CashN/A56.6541.1037.95Price / Book1.825.394.894.92Net Income-$152.63M$152.04M$119.61M$225.78M7 Day Performance-5.34%-5.54%14.55%-1.47%1 Month Performance-38.82%0.33%17.43%5.36%1 Year Performance-20.81%16.04%35.33%22.71% Kura Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KURAKura Oncology4.6099 of 5 stars$9.74-2.3%$29.38+201.6%-20.8%$757.42MN/A-4.13142MRUSMerus2.9299 of 5 stars$42.83flat$85.64+99.9%+77.9%$2.93B$43.95M-10.8437ACADACADIA Pharmaceuticals3.9246 of 5 stars$17.44+1.0%$25.60+46.8%-39.1%$2.90B$726.44M22.13510TWSTTwist Bioscience2.8772 of 5 stars$48.87+2.9%$51.90+6.2%+39.8%$2.90B$312.97M-13.19990MORMorphoSys0.0797 of 5 stars$18.96+2.4%$14.33-24.4%N/A$2.86B$238.28M-5.45730VCELVericel0.8932 of 5 stars$57.54+0.1%$59.71+3.8%+54.0%$2.84B$226.84M957.83300Positive NewsSWTXSpringWorks Therapeutics1.9318 of 5 stars$38.16-0.4%$69.50+82.1%+11.0%$2.84B$5.45M-9.87305Positive NewsZLABZai Lab2.5159 of 5 stars$26.03-1.1%$55.00+111.3%-10.1%$2.83B$355.75M-9.512,175KYMRKymera Therapeutics2.228 of 5 stars$43.54+3.3%$53.88+23.8%+62.2%$2.82B$87.56M-18.00170GMTXGemini TherapeuticsN/A$64.89+1.0%N/A+12.7%$2.81BN/A-64.8930VERAVera Therapeutics3.5627 of 5 stars$44.33+0.6%$59.22+33.6%+174.4%$2.81BN/A-16.8840 Related Companies and Tools Related Companies MRUS Alternatives ACAD Alternatives TWST Alternatives MOR Alternatives VCEL Alternatives SWTX Alternatives ZLAB Alternatives KYMR Alternatives GMTX Alternatives VERA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KURA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kura Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KURA Stock Alerts